Company

Vesigen, Inc.

Vesigen, Inc. of Cambridge develops epigenetic reprogramming therapies and the eTurna lipid nanoparticle delivery platform.

About

Founded in 2019 and based in Cambridge, US, Vesigen, Inc. develops epigenetic reprogramming therapies aimed at restoring cellular function and addressing age-related conditions. Its core technologies are ERA, which uses mRNA to influence the cellular epigenome, and the eTurna lipid nanoparticle delivery platform. Robert Millman is the founder and CEO. In July 2020, the company raised USD 28.5 mn in Series A funding led by Leaps by Bayer and Morningside Group.

1Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in